Latest news with #TrilliantHealth
Yahoo
3 days ago
- Business
- Yahoo
Trilliant Health collaborates with Duke Health to support decision making
Trilliant Health has announced a partnership with US-based health system Duke Health to enhance data-informed decision-making. This strategic alliance will utilise Trilliant's analytics platform to support network design, growth planning, and access of the patients, in line with the needs and behaviours of the communities Duke Health serves. Duke Health chief strategy officer Morgan Jones said: 'Our ability to plan effectively for strategic growth is dependent upon understanding the communities we serve. 'Applying predictive analytics allows us to understand real patterns of care, behaviour and community need.' Trilliant Health's tools will provide Duke Health with predictive analytics for facility and service planning, customised to the requirements of local communities. The solutions will also offer psychographic segmentation for patient engagement, and network integrity analysis to enhance referral retention. Additionally, these tools are designed to help pinpoint underserved areas, enhancing delivery of service, and inform consumer outreach and marketing efforts. Trilliant Health president and CEO Hal Andrews said: 'By integrating data science and behavioral insight into strategic planning, health systems can better position themselves to meet the evolving expectations of healthcare consumers.' The partnership is set to enhance patient satisfaction and loyalty, optimise utilisation of capital, and increase access to healthcare. It comes at a time when the healthcare industry is increasingly moving towards outpatient and unconventional settings, providing a scalable, evidence-based foundation for growth. In May this year, Duke Health expanded its specialty pharmacy services through a partnership with Shields Health Solutions. The collaboration is aimed at advancing clinical care and improving health outcomes in North Carolina through the expansion. "Trilliant Health collaborates with Duke Health to support decision making" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Newsweek
28-04-2025
- Health
- Newsweek
Gen Z Is Leading a New Weight Loss Trend: Ozempic Microdosing
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As Ozempic use skyrockets across America, Generation Z is fueling a new weight loss trend, according to a new survey from healthcare software company Tebra. Many Americans are taking GLP-1 medications, which include weight loss and diabetes medications Ozempic and Wegovy. However, Gen Z specifically appears to be driving a microdosing trend for the medications, with nearly 9 in 10 Gen Z users saying they are or have microdosed, according to Tebra's survey. Why It Matters Ozempic is a prescription drug developed to manage blood sugar levels in patients with Type 2 diabetes. But it can also cause weight loss as a side effect due to its impact on appetite. Ozempic is one drug of many based on the naturally occurring human hormone GLP-1, which contains semaglutide and can significantly reduce appetite amongst users. Microdosing on GLP-1 medications may be done as a way for patients to save money while still losing weight or looking to avoid some of the side effects that could come along with taking larger doses of the drug. What To Know The number of people using GLP-1 mimic medications like Ozempic has skyrocketed in recent years. Between the start of 2020 and end of 2022, prescriptions rose by 300 percent across the U.S., according to healthcare analytics firm Trilliant Health. The younger generation is using these drugs slightly differently, Tebra's survey suggests. In the survey of 640 GLP-1 users, 36 percent said they have microdosed with the drug. Gen Z was leading the trend, with 89 percent of Gen Z users saying they had microdosed in the past or currently do so. Tebra said that was significantly higher than other age groups. Across all respondents who microdosed, 24 percent said they had been microdosing for six months or more, showing it may be a more sustainable way to tackle weight loss goals. It can save a significant amount of money as well. With one monthly dose of Ozempic ranging from $1,000 to $1,200, 38 percent of GLP-1 users said they were microdosing to save money. However, some users who admitted to microdosing said they later regretted it—roughly one in five. As for why people opted to microdose, avoiding side effects was the main reason for 66 percent of microdosers, while 38 percent said they did it to save money. Weight loss satisfaction did not differ between those who microdosed and those who didn't, according to Tebra. However, microdosers were 16 percent more likely to feel confident about maintaining their weight loss over time. In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023, in Los Angeles. In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023, in Los People Are Saying Tom Holland, an exercise physiologist and weight-loss expert and author of Beat the Gym & The Micro Workout Plan, previously told Newsweek: "Unfortunately the human condition is such that, when it comes to diet and exercise, we are constantly seeking the quickest fix with the least amount of effort, regardless of the costs, both monetarily as well as physically." Dr. Sharon Giese, plastic surgeon, weight loss expert and creator of the Elective Weight Loss program previously told Newsweek: "Many of these patients have tried 'everything' and have not been able to lose weight without some assistance. This is exactly the time when trying an appetite suppressant, like Ozempic or semaglutide, may work." What Happens Next? While the number of Americans using GLP-1 medications continues to be high, the side effects and the weight gain many report after stopping the drug have some questioning the drug's long-term effects. In one 2022 study, patients who stopped taking semaglutide had regained two-thirds of the weight they initially lost one year out.
